Sanofi SA Total Assets
Sanofi SA total assets. Based on the latest financial reports, Sanofi SA (SAN) holds total assets worth €126.81 Billion EUR (≈ $148.25 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Sanofi SA worth for the company's overall valuation and market capitalisation.
Total Assets of Sanofi SA (1999–2025)
Total assets of Sanofi SA from 1999 to 2025. This chart illustrates how Sanofi SA's total assets have evolved over time, based on quarterly financial data. See Sanofi SA share price for real-time trading data and today's change.
Sanofi SA - Asset Composition Analysis
Sanofi SA Total Assets Breakdown (December 2025)
Sanofi SA total assets breakdown as of December 2025. Sanofi SA's total assets of €126.81 Billion consist of 24.4% current assets and 75.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.78 Billion | 6.0% |
| Accounts Receivable | €397.00 Million | 0.3% |
| Inventory | €10.21 Billion | 8.1% |
| Property, Plant & Equipment | €11.51 Billion | 9.1% |
| Intangible Assets | €26.26 Billion | 20.7% |
| Goodwill | €67.56 Billion | 53.3% |
Asset Composition Trend (1999–2025)
This chart illustrates how Sanofi SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sanofi SA (SAN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi SA's current assets represent 24.4% of total assets in 2025, a decrease from 68.0% in 1999.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, up from 3.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 73.0% of total assets, an increase from 3.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 53.3% of total assets.
Sanofi SA Competitors by Total Assets
Key competitors of Sanofi SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €612.64 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
Sanofi SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.46 | 1.75 |
| Quick Ratio | 0.73 | 1.14 | 0.79 |
| Cash Ratio | 0.27 | 0.26 | 0.00 |
| Working Capital | €2.61 Billion | €13.43 Billion | €14.51 Billion |
Sanofi SA - Advanced Valuation Insights
This section examines the relationship between Sanofi SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | €126.81 Billion |
| Market Capitalization | $95.70 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sanofi SA's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sanofi SA's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sanofi SA (1999–2025)
The table below shows the annual total assets of Sanofi SA from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €126.81 Billion ≈ $148.25 Billion |
-4.51% |
| 2024-12-31 | €132.80 Billion ≈ $155.25 Billion |
+5.01% |
| 2023-12-31 | €126.46 Billion ≈ $147.85 Billion |
+1.51% |
| 2022-12-31 | €124.58 Billion ≈ $145.65 Billion |
+3.61% |
| 2021-12-31 | €120.24 Billion ≈ $140.58 Billion |
+4.99% |
| 2020-12-31 | €114.53 Billion ≈ $133.90 Billion |
+1.59% |
| 2019-12-31 | €112.74 Billion ≈ $131.80 Billion |
+1.19% |
| 2018-12-31 | €111.41 Billion ≈ $130.25 Billion |
+11.62% |
| 2017-12-31 | €99.81 Billion ≈ $116.69 Billion |
-4.64% |
| 2016-12-31 | €104.67 Billion ≈ $122.37 Billion |
+2.30% |
| 2015-12-31 | €102.32 Billion ≈ $119.62 Billion |
+5.06% |
| 2014-12-31 | €97.39 Billion ≈ $113.86 Billion |
+1.39% |
| 2013-12-31 | €96.06 Billion ≈ $112.30 Billion |
-4.34% |
| 2012-12-31 | €100.41 Billion ≈ $117.39 Billion |
-0.26% |
| 2011-12-31 | €100.67 Billion ≈ $117.69 Billion |
+18.07% |
| 2010-12-31 | €85.26 Billion ≈ $99.68 Billion |
+6.51% |
| 2009-12-31 | €80.05 Billion ≈ $93.59 Billion |
+11.20% |
| 2008-12-31 | €71.99 Billion ≈ $84.16 Billion |
+4.33% |
| 2007-12-31 | €69.00 Billion ≈ $80.67 Billion |
-7.09% |
| 2006-12-31 | €74.27 Billion ≈ $86.83 Billion |
-14.58% |
| 2005-12-31 | €86.94 Billion ≈ $101.65 Billion |
+1.80% |
| 2004-12-31 | €85.41 Billion ≈ $99.85 Billion |
+777.62% |
| 2003-12-31 | €9.73 Billion ≈ $11.38 Billion |
+2.79% |
| 2002-12-31 | €9.47 Billion ≈ $11.07 Billion |
-5.01% |
| 2001-12-31 | €9.97 Billion ≈ $11.65 Billion |
+27.05% |
| 2000-12-31 | €7.84 Billion ≈ $9.17 Billion |
+14.96% |
| 1999-12-31 | €6.82 Billion ≈ $7.98 Billion |
-- |
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more